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Purpose: Thyroid cancer is the most common malignancy in Korean females and 
can be treated with good prognosis. However, drugs to treat aggressive types of 
thyroid cancer such as poorly differentiated or anaplastic thyroid cancer have not 
yet been established. To that end, we analyzed the effects of berberine on human 
thyroid cancer cell lines to determine whether this compound is useful in the treat-
ment of aggressive thyroid cancer. Materials and Methods: The two thyroid can-
cer cell lines 8505C and TPC1, under adherent culture conditions, were treated 
with berberine and analyzed for changes in cell growth, cell cycle duration, and 
degree of apoptosis. Results: Following berberine treatment, both cell lines 
showed a dose-dependent reduction in growth rate. 8505C cells showed signifi-
cantly increased levels of apoptosis following berberine treatment, whereas TPC1 
cells showed cell cycle arrest at the G0/G1 phase. Immunobloting of p-27 expres-
sion following berberine treatment showed that berberine induced a little up-regu-
lation of p-27 in 8505c cells but relatively high up-regulation of p-27 in TPC1 
cells. Conclusion: These results suggest that berberine treatment of thyroid cancer 
can inhibit proliferation through apoptosis and/or cell cycle arrest. Thus, berberine 
may be a novel anticancer drug for the treatment of poorly differentiated or ana-
plastic thyroid cancer.
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INTRODUCTION
Thyroid cancer is the most prevalent endocrine malignancy, and its incidence has 
been increasing.1,2 Well-differentiated thyroid carcinoma has a favorable prognosis 
with surgical and radioactive iodine therapy. Other thyroid malignancies such as 
poorly differentiated thyroid carcinomas and anaplastic thyroid carcinomas fre-
quently metastasize, precluding patients from a curative resection. Therapeutic op-
tions for these patients include additional surgery for resectable lesions, external 
radiotherapy and chemotherapy. The result of this approach is usually disappoint-
ing and the use of novel therapeutic approaches is needed. Poorly-differentiated thy-Berberine Inhibition of Thyroid Cancer Cell Growth
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cells were washed with PBS and cultured in fresh media. 
Berberine (Sigma, Cat no: B3412, 95% purity, Stock solu-
tion; 100 mM in dH2O) was added at 1 μM, 10 μM, or 100 
μM for 72 hours. Cells were then counted in a Neubauer 
chamber after incubation with 0.4% trypan blue dye.  
Cell cycle analysis 
After 10 μM berberine treatment for 72 hours, the cells 
were harvested, fixed in 70% ethanol for 1 hour, and washed 
with PBS. Cells were treated with 100 μg/mL RNase A for 
1 hour at 37°C, and stained with 10 μg/mL propidium io-
dide (PI). Flow cytometry was performed in triplicate for 
each experiment using a FACS Caliber system (BD Biosci-
ences, San Jose, CA, USA).  
Apoptosis analysis with annexin V staining
To analyze apoptosis, the cells treated with 10 μM berberine 
for 72 hours, and then both floating and adherent cells were 
harvested. Annexin V staining was performed according to 
the manufacturer’s protocol (BD Pharmingen, Franklin 
Lakes, NJ, USA). Trypsin-EDTA was used to obtain single-
cell suspensions. After centrifugation, cells were washed 
twice with cold PBS and resuspended in binding buffer (10 
mM HEPES, pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM 
MgCl2, and 1.8 mM CaCl2) at a concentration of 1×106 
cells/mL. An aliquot (100 μL) of the solution containing 
1×105 cells was transferred to a 5-mL culture tube, and 5 
μL each of Annexin V-FITC and PI were added. After vor-
texing, cells were incubated for 15 minutes at room temper-
ature (25°C) in the dark and 400 μL of 1X binding buffer 
was added to each tube. Flow cytometry was performed us-
ing a FACS Caliber system within 1 hour.
Expression of p27 by immunoblotting following 
berberine treatment
Cells were detached using trypsin, collected by centrifuga-
tion, and cultured as described above. Cells were treated 
with 10 μM berberine for 72h, and total cell lysates were 
collected by 200 μL lysis buffer according to the manufac-
turer’s protocol (Cell Signaling Technology, Beverly, MA, 
USA). To analyze expression of p27, protein concentration 
was measured using a Bio-Rad Protein Assay kit (Bio-Rad 
Laboratories, Hercules, CA, USA) according to the manu-
facturer’s directions. Equal amounts of cell lysates were sep-
arated by 10% SDS-PAGE. The blocking of blots was pro-
cessed with a 10% blocking buffer [10% nonfat dry milk in 
Tris-buffered saline (TBS) containing 0.1% Tween 20] for 
roid carcinoma and anaplastic thyroid carcinoma, which are 
thought to be dedifferentiated forms of pre-existing differen-
tiated tumors, do not respond well to medical and surgical 
treatment. There are several therapeutic methods, including 
surgery, radioactive iodine therapy, and thyroid stimulating 
hormone suppression by thyroid hormone replacement, for 
treating thyroid cancer. Most thyroid cancers are well differ-
entiated types and can be cured with ease through surgery 
and radioactive iodine therapy. However, poorly differentiat-
ed or anaplastic thyroid cancer shows rapid progression and 
is difficult to cure.
Berberine, isolated from the roots of herbal plants, is a 
natural compound that is non-toxic to humans.3 Berberine 
has been used as an agent for the treatment of inflammatory 
disease such as rheumatoid arthritis due to its anti-inflamma-
tory activities.4 Berberine also can control several physical 
activities, including lowering-cholesterol5 and maintenance 
of insulin levels.6 Anti-cancer activity of berberine against a 
variety of cancer cell lines has been introduced. Berberine 
exhibits antitumor effects by inhibiting the growth,7 inva-
sion,8 and metastatic ability9 of several cancers, including 
Ehrlich ascites carcinoma,10 lung cancer,11 epidermoid car-
cinoma,12 leukemia,13 cervical cancer14 and breast cancer.15 
Though anticancer activity of berberine has been reported 
in many articles, its effect on thyroid cancer has not been 
demonstrated. 
To observe the effects of berberine on thyroid cancer, we 
selected two cell lines, 8505C and TPC1. The 8505C cell 
line has been used to model anaplastic thyroid cancer, and 
the TPC1 cell line to model papillary thyroid cancer.16 
MATERIALS AND METHODS
　　　
Cell culture
Unless otherwise specified, all reagents were purchased 
from Sigma (St. Louis, MO, USA). 8505C and TPC1 cells 
were cultured on tissue culture dishes (Falcon; Cat no: 
353003, San Jose, CA, USA) in Dulbecco’s Modified Ea-
gle’s Medium (DMEM) containing 10% fetal bovine serum 
(FBS). For culture, 5×105 cells were cultured at 37°C in a 
humidified atmosphere containing 5% CO2. 
Assessment of cell growth following berberine 
treatment  
For each cell line, 5×105 cells were seeded on tissue culture 
dishes in DMEM containing 10% FBS. After 24 hours, the Kyoung Sik Park, et al.
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aplastic thyroid cancer cell line 8505C and the papillary 
thyroid cancer cell line TPC1. Both cell lines were treated 
with berberine at several concentrations (Fig. 1). After 72 
hours of treatment, growth was inhibited in a dose-depen-
dent manner in both cell lines (Fig. 1). These results show 
IC50 of berberine at 10 μM in both cell lines. Thus, 10 μM 
of berberine was selected for the analysis of the cell cycle 
and Anexin V staining in both cell lines.
Analysis of cell cycle and apoptosis in berberine-treated 
cells
Berberine is known to be an inducing drug for cell cycle ar-
rest and apoptosis. To determine whether growth inhibition 
was a result of cell cycle arrest, apoptosis, or a combination 
of both, we analyzed the DNA content of the treated cells 
by propidium iodide staining and flow cytometry. Growth 
was inhibited in both cell lines following berberine treat-
ment. In cell cycle analysis using propidium iodide staining, 
berberine induced a 2% increase in G2/M arrest at 10 μM in 
8505C cells (Fig. 2A), whereas TPC1 cells showed a 6% in-
crease in the G0/G1 phase at 10 μM of berberine (Fig. 2B). 
The cell lines showed different apoptotic responses to ber-
berine treatment. In the Annexin V staining, berberine at 10 
μM induced a 7% increase in Annexin V-FITC positive and 
PI negative 8505C cells (Fig. 3A), but no increase was de-
tected in Annexin V-FITC positive and PI negative TPC1 
cells (Fig. 3B).
Expression of p-27 protein in berberine-treated cells
We found that growth inhibition was caused by cell cycle ar-
1 h. Primary anti-p27 mouse monoclonal immunoglobulin 
G (IgG) antibody (1 : 1000; Cell Signaling Technology, 
Beverly, MA, USA) and anti-β-actin mouse monoclonal 
IgG antibody (1 : 1000, Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) were incubated overnight at 4°C, and 
were washed three times in TBS containing 0.1% Tween 20 
and secondary peroxidase-conjugated Affinipure rabbit an-
ti-mouse IgG (1 : 2500, Jackson ImmunoResearch Labora-
tories, West Grove, PA, USA) or peroxidase-conjugated Af-
finipure mouse anti-rabbit IgG for 1 h at room temperature. 
Blots of p27proteins were detected with an enhanced che-
miluminescence detection system (Amersham Bioscience, 
Piscataway, NJ, USA).
Statistical analysis 
All data were compiled from a minimum of three replicate 
experiments. Data for statistical analysis were expressed as 
the mean±standard error. Comparisons of results from treat-
ed versus control cells were performed using Student’s t-
tests. A p-value of less than 0.05 was considered statistical-
ly significant.
 
RESULTS
 
Berberine treatment inhibited 8505C and TPC1 cell 
growth in a dose-dependent manner  
We previously reported the effects of berberine in a meta-
static breast cancer model.15 To observe the effects of ber-
berine on thyroid cancer, we selected two cell lines, the an-
Fig. 1. Berberine inhibited growth of 8505C and TPC1 cell lines. 8505C (A) and TPC1 (B) cells were treated with distilled water (CTL) or ber-
berine at 1 µM, 10 µM, or 100 µM. Cells were stained with trypan blue to determine cell viability, and counted using a hematocytometer. 
Relative cell growth rates are shown as percent survival versus control cells after berberine treatment. The rectangles indicate IC 50 of 
berberine in both cell lines. The data represent the means of at least three independent experiments and the corresponding standard er-
rors. *p-value of less than 0.05. **p-value of less than 0.01. 
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Fig. 2. Cell cycle analysis of berberine-treated 8505C and TPC1 cells. 8505C (A) and TPC1 (B) cells were treated with berberine at 10 µM 
doses for 72 hours. The percentage of cells at each stage of the cell cycle was analyzed by flow cytometry after DNA staining with prop-
idium iodide. Data from a representative experiment (from a total of three) are shown.
Fig. 3. Berberine induced apoptosis in both 8505C cells and TPC1 cells.  8505C (A) and TPC1 (B) cells were treated with berberine at 10 
µM doses for 72 hours. All cells were stained with FITC-conjugated Annexin V in a buffer containing propidium iodide and analyzed by 
flow cytometry. For each treatment, the percentage of viable cells is shown in the lower left quadrant, for which both Annexin V and 
propidium iodide levels are low. Data from a representative experiment (from a total of three) are shown. 
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cell growth in a dose-dependent manner in TPC1 cells and 
induced cell cycle arrest at the G0/G1 phase. It was con-
firmed by immunoblotting that berberine increased p27 in 
TPC1 cells. All these results suggest that berberine induced 
cell cycle arrest by induction of p27, which arrests cells at 
the G0/G1 phase of the cell cycle in TPC1 cells, and thus 
that berberine can be a novel candidate for an anti-cancer 
agent against thyroid cancer. Our results showed that berber-
ine more significantly increased the levels of p27 and was 
more likely to lead to cell cycle arrest in TPC1 cells with 
RET/PTC1 rearrangement than in 8505C cells with BRAF 
V600E mutation. P27 has been shown to be targeted by the 
BRAF/MEK/ERK signaling pathway in distinct tumors 
models such as melanoma and thyroid carcinomas.19-21 
In addition, previous studies have indicated that berber-
ine could induce apoptosis in several cancers, including 
epidermoid carcinoma,12 human leukemia HL-60 cells,13 
and Ehrlich ascites carcinoma cells.22 
Here, we also observed that berberine more strongly in-
duced apoptosis in anaplastic thyroid cancer cell line 8505C 
than in TPC1. In our experiment, berberine induced an 8% 
increase of apoptosis in Annexin V-FITC positive and PI 
negative 8505C cells but, 0% in Annexin V-FITC positive 
and PI negative TPC1 cells. Since externalization of phos-
phatidylserine occurs in the earlier stages of apoptosis, FITC 
Annexin V staining can identify apoptosis at an earlier stage 
than assays based on nuclear changes such as DNA frag-
mentation.23 Of course, we cannot confirm apoptosis using 
FITC Annexin V staining, and DNA Fragmentation assay 
should be done to clearly identify the cytotoxic or cytostatic 
activities of berberine. However, these results show that 
growth inhibition by berberine is not associated with cyto-
toxic effects but with cell cycle arrest through induction of 
p27 in TPC1 cells. 
In conclusion, we have demonstrated that berberine can 
inhibit the growth of thyroid cancer cells as a result of apop-
tosis and/or cell-cycle arrest. Thus, it is possible that berber-
rest in TPC1 cells and by apoptosis in 8505c cells following 
berberine treatment. To confirm these results, we analyzed the 
expression of p-27, which is known as the molecule involved 
in cell cycle arrest. As shown in Fig. 4, berberine induced a lit-
tle up-regulation of p-27 in 8505c cells (Fig. 4A) but relative-
ly high up-regulation of p-27 in TPC1 cells (Fig. 4B). 
DISCUSSION
Berberine is a natural compound reported to have broad an-
ticancer effects, as well as anti-inflammatory effects. We 
examined the anticancer effect of berberine on the thyroid 
cancer cell lines 8505C and TPC1, through examination of 
cell cycle and apoptosis modulation. We observed that ber-
berine treatment of these cell lines decreased growth rates 
in a dose-dependent manner. Berberine induced apoptosis 
in both cell types. However, cell cycle arrest was induced 
mainly in TPC1 cells. 
Our results showed 6% increase of the G0/G1 cell cycle in 
TPC1 cells and 2% increase of the G2/M cycle in 8505C 
cells after berberine treatment. These results are consistent 
with our immunoblotting data in which berberine induced a 
little up-regulation of p-27 in 8505c cells but relatively high 
up-regulation of p-27 in TPC1 cells after berberine treatment. 
Consistent with our results, it has been reported that cell 
growth can be inhibited by berberine through cell-cycle ar-
rest.17 Berberine has been shown to inhibit the activity of 
DNA topoisomerase II alpha17 and Cdki-Cdk-cyclin,12 and 
to induce G0/G1 cell-cycle arrest in L1210 cells3 and G2/
M-phase arrest in leukemia cells.18 Previously, we reported 
similar berberine-induced inhibition of growth through cell-
cycle arrest and apoptosis-induction in breast cancer.15 To-
gether with these reports, our results suggest that the effects 
of berberine treatment of thyroid cancer cells rely upon the 
induction of cell-cycle arrest in TPC1 cells. It was already 
demonstrated in our experiments that berberine inhibited 
Fig. 4. Expression of p-27 after berberine treatment for 72 h. 8505C (A) and TPC1 (B) cells were treated with berberine at 10 µM doses for 
72 hours. Expression of p-27 and β-actin was detected by immunoblotting. Lane 1: cells treated with distilled water (CTL); lane 2: cells 
treated with berberine at 10 µM doses. 
p27 p27
ß-actin ß-actin
CTL CTL 10 µM 10 µM A BBerberine Inhibition of Thyroid Cancer Cell Growth
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12. Mantena SK, Sharma SD, Katiyar SK. Berberine inhibits growth, 
induces G1 arrest and apoptosis in human epidermoid carcinoma 
A431 cells by regulating Cdki-Cdk-cyclin cascade, disruption of 
mitochondrial membrane potential and cleavage of caspase 3 and 
PARP. Carcinogenesis 2006;27:2018-27. 
13. Lin CC, Kao ST, Chen GW, Ho HC, Chung JG. Apoptosis of hu-
man leukemia HL-60 cells and murine leukemia WEHI-3 cells in-
duced by berberine through the activation of caspase-3. Anticancer 
Res 2006;26:227-42.
14. Mahata S, Bharti AC, Shukla S, Tyagi A, Husain SA, Das BC. 
Berberine modulates AP-1 activity to suppress HPV transcription 
and downstream signaling to induce growth arrest and apoptosis 
in cervical cancer cells. Mol Cancer 2011;10:39.
15. Kim JB, Yu JH, Ko E, Lee KW, Song AK, Park SY, et al. The al-
kaloid Berberine inhibits the growth of Anoikis-resistant MCF-7 
and MDA-MB-231 breast cancer cell lines by inducing cell cycle 
arrest. Phytomedicine 2010;17:436-40.
16. Hoffmann S, Burchert A, Wunderlich A, Wang Y, Lingelbach S, 
Hofbauer LC, et al. Differential effects of cetuximab and AEE 788 
on epidermal growth factor receptor (EGF-R) and vascular endo-
thelial growth factor receptor (VEGF-R) in thyroid cancer cell 
lines. Endocrine 2007;31:105-13.
17. Kang MR, Chung IK. Down-regulation of DNA topoisomerase 
IIalpha in human colorectal carcinoma cells resistant to a proto-
berberine alkaloid, berberrubine. Mol Pharmacol 2002;61:879-84.
18. Lin CC, Lin SY, Chung JG, Lin JP, Chen GW, Kao ST. Down-
regulation of cyclin B1 and up-regulation of Wee1 by berberine 
promotes entry of leukemia cells into the G2/M-phase of the cell 
cycle. Anticancer Res 2006;26:1097-104.
19. Bhatt KV, Hu R, Spofford LS, Aplin AE. Mutant B-RAF signaling 
and cyclin D1 regulate Cks1/S-phase kinase-associated protein 
2-mediated degradation of p27Kip1 in human melanoma cells. 
Oncogene 2007;26:1056-66.
20. Bhatt KV, Spofford LS, Aram G, McMullen M, Pumiglia K, Aplin 
AE. Adhesion control of cyclin D1 and p27Kip1 levels is deregu-
lated in melanoma cells through BRAF-MEK-ERK signaling. 
Oncogene 2005;24:3459-71.
21. Preto A, Gonçalves J, Rebocho AP, Figueiredo J, Meireles AM, 
Rocha AS, et al. Proliferation and survival molecules implicated 
in the inhibition of BRAF pathway in thyroid cancer cells har-
bouring different genetic mutations. BMC Cancer 2009;9:387.
22. Letasiová S, Jantová S, Miko M, Ovádeková R, Horváthová M. 
Effect of berberine on proliferation, biosynthesis of macromole-
cules, cell cycle and induction of intercalation with DNA, dsDNA 
damage and apoptosis in Ehrlich ascites carcinoma cells. J Pharm 
Pharmacol 2006;58:263-70.
23. Koopman G, Reutelingsperger CP, Kuijten GA, Keehnen RM, 
Pals ST, van Oers MH. Annexin V for flow cytometric detection 
of phosphatidylserine expression on B cells undergoing apoptosis. 
Blood 1994;84:1415-20.
ine could be a novel anticancer drug for the treatment of 
poorly differentiated or anaplastic thyroid cancer.  
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